Index»
approval
»
fda
»
januvia™
»
mercks
»
receives
»
Mercks Januvia™ Receives FDA Approval
On October 17, 2006, the FDA approved Mercks Januvia™ for type 2 diabetes.
Januvia (sitagliptin) is an incretin enhancer. For a brief primer on how these drugs work, visit our post:
New Diabetes Drugs on the Horizon: Incretin Enhancers
Merck states the recommended dose as 100 mg/day. The 100 mg tablets will be available in pharmacies in the near future. Price: $4.86/tablet.
________
For FDAs press release:
FDA Approves New Treatment for Diabetes
For Mercks press release:
FDA Approves Once-Daily JANUVIA™, the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes
For Januvias site:
Januvia
Mercks Januvia™ Receives FDA Approval
Tuesday, April 15, 2014
On October 17, 2006, the FDA approved Mercks Januvia™ for type 2 diabetes.
Januvia (sitagliptin) is an incretin enhancer. For a brief primer on how these drugs work, visit our post:
New Diabetes Drugs on the Horizon: Incretin Enhancers
Merck states the recommended dose as 100 mg/day. The 100 mg tablets will be available in pharmacies in the near future. Price: $4.86/tablet.
For FDAs press release:
FDA Approves New Treatment for Diabetes
For Mercks press release:
FDA Approves Once-Daily JANUVIA™, the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes
For Januvias site:
Januvia
Related Posts : approval,
fda,
januvia™,
mercks,
receives
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment